Actuate Therapeutics Shares Outstanding History (ACTU)
Actuate Therapeutics reported 23.2M shares outstanding at the end of fiscal 2025.
View full Actuate Therapeutics company overviewActuate Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 23.2M | 3.7M | +19.01% |
| 2024 | 2024-12-31 | 19.5M | 17.8M | +1055.20% |
| 2023 | 2023-12-31 | 1.7M | −17.4M | −91.15% |
| 2022 | 2022-12-31 | 19.1M | — | — |
Actuate Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 24.0M | 3.5M | +17.31% |
| Q1 2026 | 2026-03-31 | 23.7M | 4.2M | +21.40% |
| Q4 2025 | 2025-12-31 | 23.2M | 3.7M | +19.01% |
| Q3 2025 | 2025-09-30 | 23.2M | 3.7M | +19.00% |
| Q2 2025 | 2025-06-30 | 20.5M | 18.8M | +1110.73% |
| Q1 2025 | 2025-03-31 | 19.5M | — | — |
| Q4 2024 | 2024-12-31 | 19.5M | 17.8M | +1055.20% |
| Q3 2024 | 2024-09-30 | 19.5M | — | — |
| Q2 2024 | 2024-06-30 | 1.7M | — | — |
| Q4 2023 | 2023-12-31 | 1.7M | — | — |
Actuate Therapeutics shares outstanding trends
Between the periods ended 2022-12-31 and 2025-12-31, Actuate Therapeutics's shares outstanding moved from 19.1M to 23.2M, a change of 4.1M. The latest reported quarter, Q2 2026, shows 24.0M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Actuate Therapeutics source filings ↗